407 related articles for article (PubMed ID: 23705574)
21. Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.
Strand J; Varasteh Z; Eriksson O; Abrahmsen L; Orlova A; Tolmachev V
Mol Pharm; 2014 Nov; 11(11):3957-64. PubMed ID: 24972112
[TBL] [Abstract][Full Text] [Related]
22. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
23. Comparative preclinical evaluation of
Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
[TBL] [Abstract][Full Text] [Related]
24. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
25. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
26. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
27. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
28. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
29. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.
Rosik D; Thibblin A; Antoni G; Honarvar H; Strand J; Selvaraju RK; Altai M; Orlova A; Eriksson Karlström A; Tolmachev V
Bioconjug Chem; 2014 Jan; 25(1):82-92. PubMed ID: 24344772
[TBL] [Abstract][Full Text] [Related]
32. ⁶⁸Ga-NODAGA-VEGF₁₂₁ for in vivo imaging of VEGF receptor expression.
Kang CM; Koo HJ; Choe YS; Choi JY; Lee KH; Kim BT
Nucl Med Biol; 2014 Jan; 41(1):51-7. PubMed ID: 24183611
[TBL] [Abstract][Full Text] [Related]
33. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
34. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
[TBL] [Abstract][Full Text] [Related]
35. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
[TBL] [Abstract][Full Text] [Related]
36. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
[TBL] [Abstract][Full Text] [Related]
37. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
[TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
Altai M; Varasteh Z; Andersson K; Eek A; Boerman O; Orlova A
Cancer Biother Radiopharm; 2013 Apr; 28(3):187-95. PubMed ID: 23461385
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
